Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Duster340 on Aug 10, 2021 12:32pm

From May/6/2020

“The world is in desperate need of safer therapies for pain and inflammation,” Dr Stauffer said. “Antibe represents one of the few truly novel platforms in the field, and I look forward to playing a role in navigating its drug pipeline through the later stages of clinical development, and ultimately providing patients with a safer treatment paradigm for pain management.”

In connection with Dr Stauffer’s appointment, the company has granted him a total of 500,000 restricted share units (RSUs). All RSUs are subject to time-based vesting; one-third of the RSUs granted will vest on each of the first, second and third anniversaries of today’s date.)
Duster340 writes: lets say the stock price was @ $4.00 on may/6th/2021 stauffer got 1/3 of 500k which is 166.66k x 4 = 666.64 thousand not bad. even at $1.50 per share he would have made a cool 250 thousand all these guys are getting paid huge money regardless of how the stock performs. how did you guys make out.  it,s a scam they have a drug that is not what they pump it up to be, all they have to do is drag it out as many years as possible and they get rich off of the rsu's. they are not alone how many other companies do you know of that where hyped, and then crashed and burned, the old pump and dump, totaly legal though, the rich get richer while share holders pay the price. i feel sorry for you guys. i hope this is not the case here but will only be known in time.
glta

Comment by IrishCanuck on Aug 10, 2021 1:19pm
Those three paragraphs have no coherent connection
Comment by Rarbar99 on Aug 10, 2021 6:30pm
Dr. Staffer was the global medical director at Abbot Labs, a company that has a $250 BILLION dollar market cap. And you think he's going to put his reputation on the line to swindle for $500K? do your research before you attempt to spread fud.
Comment by Duster340 on Aug 10, 2021 8:00pm
Comment by MikeStock on Aug 10, 2021 8:10pm
I'm ashamed to even be responding to this nonsense. Check your dates and your facts. The 500K shares was pre-split. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities